Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 5/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL1847412 | 1.00 | ALDH1A1 (0.40) | ALDH1A1RAB9AMEN1KMT2AACE | |
| Phenol SCHEMBL28162156 | 1.00 | ALDH1A1 (0.40) | ALDH1A1RAB9AMEN1KMT2AACE | |
| Phenol SCHEMBL27348628 | 0.91 | ALDH1A1 (0.46) | ALDH1A1RAB9AMEN1KMT2AITGB2 | |
| Phenol SCHEMBL28342610 | 0.91 | ALDH1A1 (0.46) | ALDH1A1RAB9AMEN1KMT2AITGB2 | |
| Benzene SCHEMBL28092853 | 0.88 | ECE1 (0.39) | ALDH1A1RAB9AMEN1KMT2AITGB2 | |
| Phenol SCHEMBL170523 | 0.83 | ALDH1A1 (0.39) | ALDH1A1RAB9AMEN1KMT2AHPGDS | |
| Phenol SCHEMBL29254468 | 0.83 | ALDH1A1 (0.39) | ALDH1A1RAB9AMEN1KMT2AHPGDS | |
| SCHEMBL3856802 | 0.83 | ECE1 (0.42) | ITGB2ICAM1ITGAL | |
| SCHEMBL7034111 | 0.83 | ECE1 (0.42) | ITGB2ICAM1ITGAL | |
| SCHEMBL29181774 | 0.76 | KDM4E (0.43) | ALDH1A1RAB9AMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086061-A2 | NOVEL KV3 CHANNEL MODULATORS | MERCK SHARP & DOHME LLC (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-3891166-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3891165-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3891164-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3774764-A1 | BENZOTHIOPHENES AND RELATED COMPOUNDS AS STING AGONISTS | Merck Sharp&Dohme Corp. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3774765-A1 | AZA-BENZOTHIOPHENE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3709986-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3710444-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3692053-A1 | IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-2020117625-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-11 | — | — | WO | disclosed |
| EP-1948165-A1 | PHARMACEUTICAL COMBINATION COMPRISING ATORVASTATIN DERIVATIVES | Ranbaxy Laboratories Limited (IN) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007060627-A2 | USE OF MACROLIDE DERIVATIVES FOR TREATING ACNE | RANBAXY LABORATORIES LIMITED (IN) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007054789-A1 | PHARMACEUTICAL COMBINATION COMPRISING ATORVASTATIN DERIVATIVES | RANBAXY LABORATORIES LIMITED (IN) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007039809-A1 | METABOLITES OF 2- {3-[4-(5-FLUORO-2-ISOPROPOXY-PHENYL)-PIPERAZIN-1-YL]-PROPYL} -5,6-DIHYDROXY-HEXAHYDRO-ISOINDOLE-1,3-DIONE | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-12 | — | — | WO | disclosed |
| EP-1746998-A1 | COMBINATION THERAPY FOR LOWER URINARY TRACT SYMPTOMS | RANBAXY LABORATORIES, LTD. (IN) | 2007-01-31 | — | — | EP | disclosed |
| WO-2006092710-A1 | METABOLITES OF 2-{3-[4-(2-ISOPROPOXYPHENYL) PIPERAZIN-1-YL]-PROPYL}-3A,4,7,7A-TETRAHYDRO-1H-ISOINDOLE-1,3-(2H)-DIONE | RANBAXY LABORATORIES LIMITED (IN) | 2006-09-08 | — | — | WO | disclosed |
| WO-2005092342-A1 | COMBINATION THERAPY FOR LOWER URINARY TRACT SYMPTOMS | RANBAXY LABORATORIES LIMITED (IN) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092341-A1 | COMBINATION THERAPY FOR LOWER URINARY TRACT SYMPTOMS | RANBAXY LABORATORIES LIMITED (IN) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005018643-A1 | METABOLITES OF 1-{3-4`4-(2-METHOXYPHENYL) PIPERAZIN-1-YL!-PROPYL}-PIPERIDINE-2, 6-DIONE FOR USE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | RANBAXY LABORATORIES LIMITED (IN) | 2005-03-03 | — | — | WO | disclosed |
| CN-1391575-A | Nitrogen containing heterobicycles as factor XA inhibitors | DU PONT PHARM CO (US) | 2003-01-15 | — | — | CN | disclosed |